Katherine D Crew, MD

Expertise in: 
Cancer Care
Board Certifications: 
Internal Medicine, Medical Oncology
Accepting New Patients
Virtual Visits/Telehealth
Profile Headshot

Overview

Katherine D. Crew, M.D., M.S. is an Associate Professor of Medicine and Epidemiology at the NewYork-Presbyterian/Columbia University Medical Center. Dr. Crew cares for patients with breast cancer and women at high-risk for breast cancer.

Dr. Crew received her undergraduate B.S. in Biochemistry from Brown University, where she graduated Magna Cum Laude. She received her M.D. from Columbia University College of Physicians and Surgeons and her M.S. from Columbia University School of Public Health. She completed her Internal Medicine residency and Medical Oncology fellowship at NewYork-Presbyterian/Columbia University Medical Center. Dr. Crew is currently involved in patient care, clinical research, and teaching on the Breast Oncology service.

Areas of Expertise / Conditions Treated

  • Breast Cancer
  • High Risk Breast Disease

Academic Appointments

  • Associate Professor of Medicine and Epidemiology at the Columbia University Medical Center

Administrative Titles

  • Director of Clinical Breast Cancer Prevention Program at CUMC
  • Director of DataBase Shared Resource at HICCC

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Languages

  • Spanish

Gender

  • Female

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

161 Fort Washington Avenue
New York, NY 10032

Insurance Accepted

Aetna

  • Aetna Signature Administrators
  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Student Health

Affinity Health Plan

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs

Amida Care

  • Special Needs

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West (National)
  • HMO
  • POS
  • PPO

Elderplan

  • Medicare Managed Care

Emblem/GHI

  • Medicare Managed Care
  • PPO

Empire Blue Cross/Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Health First

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Health Insurance Plan of NY (HIP)

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Health Plus - Amerigroup

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare

Medicare

  • Traditional Medicare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

United Health Care

  • Columbia Employee POS
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE SelectHealth

  • Medicare Managed Care
  • Select Health
  • Special Needs

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • Columbia University College of Physicians and Surgeons
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Board Certifications

  • Internal Medicine
  • Medical Oncology

Honors & Awards

1996-1997 Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, Laboratory of Chemoprevention, National Cancer Institute

2003-2005 Full Scholarship for Masters in Biostatistics, Patient Oriented Research Track, Mailman School of Public Health, Columbia University

2006 Southwest Oncology Group Young Investigators Training Course

2006-2010 NIH Loan Repayment Program Award

Research

Dr. Crew’s research involves the development of early phase clinical trials for evaluating chemopreventive agents for breast cancer. These studies implement intermediate markers for breast cancer risk, such as mammographic density, tissue- and serum-based biomarkers. In a presurgical study design, women with newly diagnosed breast cancer are given a short-term drug administration during the interval between breast biopsy and surgical resection to test the biologic activity of the drug in breast tumor tissue. In the phase I/II setting, clinical trials are underway to study high-dose vitamin D and a green tea extract, Polyphenon E, in high-risk women.

 
Dr. Crew also participates in multicenter breast cancer chemoprevention trials through the Phase I/II Chemoprevention Trials Consortium and the Southwest Oncology Group (SWOG). The overall goal of this research is to build a comprehensive, interdisciplinary breast cancer prevention program, which will offer preventive strategies to breast cancer patients and healthy, high-risk women.
 
Dr. Crew is actively studying how to better identify women at high-risk for breast cancer in the primary care setting using patient-centered decision aids and provider-centered decision support tools embedded within the electronic health record. The overall goal of this work is to adopt risk-appropriate breast cancer screening and prevention strategies.

Grants

Present Support:

Federal:

Columbia/Cornell/Harlem Hospital Precision Medicine Initiative HPO

Period: 07/01/16-06/30/21

PI: Goldstein, D

Direct Cost: $30,445,533

Funding Agency: National Institutes of Health - 1UG3OD023183-01

Impact of HIV and ART on breast cancer treatment and outcomes in South Africa

Period: 10/01/15-09/31/20

Multi-PIs: Ruff P, Joffe M, Neugut A; Co-I: Crew KD

Direct Cost: $1,617,383

Funding Agency: National Cancer Institute – R01 CA192627-01

Increasing breast cancer chemoprevention in the primary care setting

Period: 05/01/14-04/30/19

Multi-PIs: Crew, KD; Kukafka, R

Direct Cost: $2,049,199

Funding Agency: National Cancer Institute – R01 CA177995-01A1

Acupuncture for aromatase inhibitor-related arthralgias in breast cancer patients

Period: 09/01/11-08/31/17 (no cost extension)

PI: Hershman, DL; Co-I: Crew, KD

Direct Cost: $1,956,552

Funding Agency: National Center for Complimentary and Alternative Medicine – R01 AT006376-01

Cancer Center Support Grant

Period: 07/01/03-06/30/19

PI: Emerson, S; Director of DataBase Shared Resource: Crew, KD

Direct Cost: $2,216,371

Funding Agency: National Cancer Institute – 5 P30 CA013696-39

SWOG NCORP Research Base

Period: 08/01/14-07/31/19

PI: Blanke, C; Executive Officer, Prevention and Survivorship Committees: Crew, KD

Direct Cost: $6,084,007

Funding Agency: National Cancer Institute – 5UG1CA189974-02

SWOG/Hope Virtual Grant-Writing Workshop

Period: 01/01/15-12/31/17

Course Director: Crew, KD

Direct Cost: $30,061

Funding Agency: Hope Foundation

Foundation:

Development of a decision aid on BRCA genetic testing for Orthodox Jewish women

Period: 07/01/16-06/30/18

PI: Trivedi, M; Mentor: Crew, KD

Direct Cost: $120,000

Funding Agency: Susan G. Komen Postdoctoral Fellowship Grant - PDF16378127

Institutional:

Pilot biomarker modulation study of metformin and omega-3 fatty acids in women with a history of early stage breast cancer

Period: 01/01/14-12/31/17

PI: Hershman, DL; Project PI: Crew, KD

Total Cost: $297,000

Funding Agency: Witten Breast Cancer Research Fund

Past Support:

Development of a decision aid to enhance risk-stratified breast cancer screening in a multi-ethnic cohort of women

Period: 01/01/16-12/31/16

PI: Crew, KD

Total Cost: $50,000

Funding Agency: Avon Foundation – Breast Cancer Disparities

Phase IIb randomized, double-blinded, placebo-controlled biomarker modulation study of high dose vitamin D in premenopausal women at high-risk for breast cancer

Period: 11/01/11-10/31/16

PI: Crew, KD

Contracted to sites - $2,500 per patient

Funding Agency: National Cancer Institute – SWOG 0812

Developing a culturally tailored decision aid for BRCA genetic testing for Orthodox Jews

Period: 09/01/15-08/31/16

PI: Crew, KD

Total Cost: $75,000

Funding Agency: Basser Innovation Award

Evaluating mental illness as a barrier to genetic testing for hereditary breast cancer in a multi-ethnic cohort

Period: 01/01/15-12/31/15

PI: Crew, KD

Total Cost: $75,000

Funding Agency: Avon Foundation – Breast Cancer Disparities

Understanding social, cultural, and religious factors influencing BRCA genetic testing in the Orthodox Jewish community

Period: 12/01/14-11/31/15

PI: Crew, KD

Total Cost: $40,000

Funding Agency: Irving Institute for Clinical and Translational Research – Community Based Participatory Research Pilot

When numbers matter: Decision support for BRCA genetic testing

Period: 09/01/14-08/31/15

PI: Crew, KD

Total Cost: $75,000

Funding Agency: Basser External Research Grant Program

MicroRNA expression in benign breast tissue as a biomarker of breast cancer risk

Period: 07/01/13-06/30/14

PI: Sivasubramanian, P; Mentor: Crew, KD

Total Cost: $50,000

Funding Agency: Conquer Cancer Foundation Young Investigator Award

Effect of docosahexaenoic acid (DHA), an omega-3 fatty acid, on breast inflammation – A randomized pilot study in women with a history of breast cancer, premalignant lesions, and benign breast disease

Period: 01/01/13-12/31/15

PI: Hudis, C; Site PI: Crew, KD

Direct Cost: $158,728

Funding Agency: National Cancer Institute – N01-CN-35159

Increasing breast cancer chemoprevention in the primary care setting

Period: 01/01/13-12/31/13

PI: Crew, KD

Total Cost: $25,000

Funding Agency: Irving Institute for Clinical and Translational Research

Effects of tea polyphenols on the PI3K/AKT pathway in human breast cancer

Period: 07/01/11-06/30/12

PI: Campbell, J; Mentor: Crew, KD

Total Cost: $50,000

Funding Agency: Conquer Cancer Foundation Young Investigator Award

Breast cancer Family-based Intervention Trial (BFIT) planning grant

Period: 12/01/10-06/30/12

PI: Crew, KD

Total Cost: $70,000

Funding Agency: Irving Institute for Clinical and Translational Research

Chemopreventive and anticancer potential of vitamin D and rosemary on breast cancer

Period: 07/01/09-06/30/12

PI: Crew, KD

Total Cost: $180,000

Funding Agency: Irving Scholar Award

Effect of vitamin D on mammographic density in postmenopausal women at high risk for breast cancer

Period: 01/01/09-12/31/11

PI: Crew, KD

Total Cost: $100,000

Funding Agency: Avon Foundation Breast Cancer Pilot Award

Green tea for breast cancer chemoprevention: Surrogate endpoint biomarkers

Period: 04/01/08-03/31/13

PI: Crew, KD

Direct Cost: $675,000

Funding Agency: American Cancer Society Mentored Research Scholar Grant

Vitamin D for breast cancer chemoprevention

Period: 08/01/07-07/31/13

PI: Crew, KD

Total Cost: $375,000

Funding Agency: Howard Hughes Medical Institute Physician-Scientist Early Career Award

Pilot study of vitamin D in high-risk premenopausal women

Period: 07/15/07-07/14/10

PI: Crew, KD

Total Cost: $80,000

Funding Agency: Prevent Cancer Foundation

Phase IIb randomized controlled biomarker modulation study of vitamin D in high-risk premenopausal women

Period: 07/01/07-06/30/11

PI: Crew, KD

Direct Cost: $187,400

Funding Agency: American Society of Clinical Oncology Career Development Award

Post-treatment care of Latina breast cancer survivors

Period: 07/01/07-06/30/10

PI: Hershman, DL; Co-I: Crew, KD

Direct Cost: $236,258

Funding Agency: Susan G. Komen Research Award

Vitamin D status and racial disparities in breast cancer survival

Period: 06/01/07-05/30/08

PI: Crew, KD

Total Cost: $25,000

Funding Agency: Sindab Pilot Award

Vitamin D and breast cancer risk and survival

Period: 04/01/07-03/31/08

PI: Crew, KD

Total Cost: $125,000

Funding Agency: NIH, K12 UL1 RR024156

Phase Ib randomized, double-blinded, placebo-controlled, dose-escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer

Period: 01/01/07-12/31/12

PI: Hershman; Co-I: Crew, KD

Direct Cost: $291,554

Funding Agency: National Cancer Institute – N01-CN-35159

Phase II clinical trial to determine if Polyphenon E inhibits c-Met signaling and activation of pathways contributing to breast cancer progression

Period: 01/01/07-12/31/07

PI: Crew, KD

Total Cost: $15,000

Funding Agency: Mitsui Norin

Effects of physical activity and dietary change in minority breast cancer survivors

Period: 09/01/06-08/31/09

PI: Hershman, DL; Co-I: Crew, KD

Total Cost: $223,151

Funding Agency: Gateway Cancer Research Foundation

Feasibility of pre-surgical intervention studies for evaluating targeted therapies for breast cancer

Period: 07/01/06-06/30/07

PI: Crew, KD

Total Cost: $30,000

Funding Agency: Avon Foundation Breast Cancer Pilot Award

Randomized placebo controlled trial of acupuncture on joint pain induced by aromatase inhibitors in breast cancer patients

Period: 01/01/06-12/31/07

PI: Crew, KD

Direct Cost: $99,936

Funding Agency: Lance Armstrong Foundation Young Investigator Award

Pilot study on the effect of acupuncture on joint pain induced by aromatase inhibitors in breast cancer patients

Period: 07/01/05-06/30/06

PI: Hershman, DL; Co-I: Crew, KD

Total Cost: $26,570

Funding Agency: Women at Risk

Selected Publications

Peer-Reviewed Research Publications:

Khankari NK, Bradshaw PT, Steck SE, He K, Olshan AF, Ahn J, Terry MB, Crew KD, Teitelbaum SL, Neugut AI, Santella RM, Gammon MD (2017). Interaction between polyunsaturated fatty acids and genetic variants in relation to breast cancer incidence. Journal of Cancer Epidemiology and Prevention (in press).

Ackerman MG, Shapiro PA, Coe A, Trivedi MS, Crew KD (2017). The impact of mental illness on uptake of genetic counseling for hereditary breast and ovarian cancer in a multiethnic cohort of breast cancer patients. Breast Journal (in press).

Cubasch H, Ruff P, Joffe M, Norris S, Chirwa T, Nietz S, Sharma V, Duarte R, Buccimazza I, David R, Shas C, Stopforth LW, Tsai W-Y, Stavsky E, Crew KD, Jacobson JS, Neugut AI (2017). The South African breast cancer and HIV outcomes (SABCHO) study: A multi-center cohort study of HIV and breast cancer in sub-Saharan Africa. Journal of Global Oncology (in press).

Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Vogel SJ, Anderson GL, Hershman DL, Goodman GE, Brown PH, Meyskens FL, Albain KS (2017). Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology with tamoxifen for breast cancer treatment: SWOG S9630. Nature Breast (in press).

Lim EA, Gunther JE, Kim HK, Flexman M, Hibshoosh H, Crew KD, Taback B, Campbell J, Kalinsky K, Hielscher A, Hershman DL (2017). Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment [Epub ahead of print].

Kalinsky K, Zheng T, Hibshoosh H, Du X, Mundi P, Yang J, Refice S, Feldman SM, Taback B, Connolly E, Crew KD, Maurer M, Hershman DL (2017). Proteomic modulation in breast tumors after metformin exposure: Results from a "window of opportunity" trial. Clinical and Translational Oncology, 19:180-188.

Aycinena AC, Valdovinos C, Crew KD, Tsai WY, Mata JM, Sandoval R, Hershman DL, Greenlee H (2017). Barriers to recruitment and adherence in a randomized controlled diet and exercise weight loss intervention among minority breast cancer survivors. Journal of Immigrant and Minority Health, 19:120-129.

Coe AM, Ueng W, Vargas JM, David R, Vanegas A, Infante K, Trivedi M, Yi H, Dimond J, Crew KD, Kukafka R (2016). Usability testing of a web-based decision aid for breast cancer risk assessment among multi-ethnic women. American Medical Informatics Association Annual Symposium Proceedings (in press).

Tang E, Trivedi MS, Kukafka R, Chung WK, David R, Respler L, Leifer S, Schechter I, Crew KD (2016). Population-based study of attitudes toward BRCA genetic testing among Orthodox Jewish women. Breast Journal [Epub ahead of print].

Greenlee H, Gaffney AO, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Shi Z, Lim E, Tsai W-Y, Santella RM, Blaner WS, Clugston RD, Cremers S, Pollak S, Sirosh I, Crew KD, Maurer M, Kalinsky K, Hershman DL (2016). Long-term diet and biomarker changes after a short-term intervention among Hispanic breast cancer survivors: the ¡Cocinar Para Su Salud! Randomized controlled trial. Cancer Epidemiology, Biomarkers and Prevention, 25:1491-1502.

Greenlee H, Sardo Molmenti C, Crew KD, Awad D, Kalinsky K, Brafman L, Fuentes D, Shi Z, Tsai WY, Neugut AI, Hershman DL (2016). Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors. Journal of Cancer Survivorship, 10:956-963.

Greenlee H, Crew KD, Capodice J, Awad A, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi M, Kalinsky K, Hershman DL (2016). Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Research and Treatment, 156:453-464.

Yi H, Xiao T, Thomas PS, Aguirre AN, Smalletz C, Dimond J, Finkelstein J, Infanted K, Trivedi M, David R, Vargas J, Crew KD, Kukafka R (2015). Developing decision support tools for breast cancer risk communication for patients and primary care providers. American Medical Informatics Association Annual Symposium Proceedings, 2015:1352-1360. [PMCID: PMC4765687]

Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL (2015). Effects of an oral green tea extract, Polyphenon E, on systemic biomarkers of growth factor signaling in women with a history of hormone receptor-negative breast cancer. Journal of Human Nutrition and Dietetics 28:272-282. [PMCID: PMC4205214]

Ho KA, Cardelli JA, McLarty J, Hershman DL, Maurer M, Kalinsky K, Taback B, Hibshoosh H, Su T, Refice SF, Crew KD (2015). Evaluating tissue biomarker effects of an oral green tea extract, Polyphenon E, using reverse phase protein array in women with operable breast cancer. International Journal of Food Sciences, Nutrition and Dietetics 4:190-196.

Crew KD, Xiao T, Thomas PS, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice S, Kranwinkel G, Hershman DL (2015). Safety, feasibility, and biomarker effects of vitamin D supplementation among women at high-risk for breast cancer. International Journal of Food Sciences, Nutrition and Dietetics S1:001 1-9.

Chen EI, Crew KD, Trivedi M, Awad D, Maurer M, Kalinsky K, Koller A, Patel P, Kim J, Hershman DL (2015). Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS One, 10:e0145816. [PMCID: PMC4692419]

Kukafka R, Yi H, Xiao T, Thomas PS, Aguirre AN, Smalletz C, David R, Crew KD (2015). Why breast cancer risk by the numbers is not enough: Evaluation of a decision aid in multi-ethnic low-numerate women. Journal of Medical Internet Research 17:e165. [PMCID: PMC4526996]

Reimers LL, Sivasubramanian PS, Hershman DL, Terry MB, Greenlee H, Campbell J, Kalinsky K, Maurer M, Jayasena R, Sandoval R, Alvarez M, Crew KD (2015). Breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ. Breast Journal 21:377-386. [PMCID: PMC4490034]

Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, Unger JM, Lew D, Hansen L, Hershman DL (2015). Methods to standardize a multicenter acupuncture trial protocol to reduce aromatase inhibitor-related joint symptoms in breast cancer patients. Journal of Acupuncture and Meridian Studies 8:152-158. [PMCID: PMC4705910]

Greenlee H, Gaffney AO, Aycinena AC, Koch P, Contento I, Karmally W, Richardson J, Tsai WY, Crew KD, Maurer M, Kalinsky K, Hershman D (2015). Cocinar Para Su Salud!: Randomized controlled trial of a culturally-based dietary intervention among Hispanic breast cancer survivors. Journal of the Academy of Nutrition and Dietetics 115:709-723. [PMCID: PMC4499508]

Reimers LL, Crew KD, Bradshaw PT, Santella RM, Steck SE, Sirosh I, Terry MB, Hershman DL, Shane E, Cremers S, Dworakowski E, Teitelbaum SL, Neugut AI, Gammon MD (2015). Vitamin D-related genes, plasma 25-hydroxyvitamin D, and breast cancer risk. Cancer Causes Control, 26:187-203. [PMCID: PMC4302042]

McCullough LE, Eng SM, Bradshaw PT, Cleveland RJ, Steck SE, Terry MB, Shen J, Crew KD, Rossner P, Ahn J, Ambrosone CB, Teitelbaum SL, Neugut AI, Santella RM, Gammon MD (2015). Genetic polymorphisms in DNA repair and oxidative stress pathways may modify the association between body size and postmenopausal breast cancer. Annals of Epidemiology, 25:263-269. [PMCID: PMC4369423]

Delgado-Cruzata L, Zhang W, McDonald JA, Tsai WY, Valdovinos C, Falci L, Wang Q, Crew KD, Santella RM, Hershman DL, Greenlee H (2015). Dietary modifications, weight loss and changes in metabolic markers effect global DNA methylation in Hispanic, African American and Afro-Caribbean breast cancer survivors. Journal of Nutrition, 145:783-790. [PMCID: PMC4381766]

Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL, Meyskens FL, Moinpour CM (2015). Randomized multicenter placebo-controlled trial of omega-3-fatty acids for the control of aromatase inhibitor-induced musculoskeletal pain (S0927). Journal of Clinical Oncology 33:1910-1917. [PMCID: PMC4451174]

Crew KD, Campbell J, Reynolds D, Fulton L, Flom J, Liao Y, Tehranifar P, Terry MB (2014). Mammographic density and serum 25-hydroxyvitamin D levels. Nutrition and Metabolism 11:18. [PMCID: PMC3996501]

Work ME, Reimers LL, Quante AS, Crew KD, Whiffen A, Terry MB (2014). Changes in mammographic density over time in breast cancer cases and women at high risk for breast cancer. International Journal of Cancer 135:1740-1744. [PMCID: PMC4107003]

McCullough LE, Santella RM, Cleveland RJ, Millikan RC, Olshan AF, North KE, Bradshaw PT, Eng SM, Terry MB, Shen J, Crew KD, Rossner P, Teitelbaum SL, Neugut AI, Gammon MD (2014). Polymorphisms in DNA repair genes, recreational physical activity, and breast cancer risk. International Journal of Cancer 134:654-663. [PMCID: PMC3830595]

Khankari NK, Bradshaw PT, McCullough LE, Teitelbaum SL, Steck SE, Fink BN, Xu X, Ahn J, Ambrosone CB, Crew KD, Terry MB, Neugut AI, Chen J, Santella RM, Gammon MD (2014). Genetic variation in multiple biologic pathways, flavonoid intake, and breast cancer. Cancer Causes Control 25:215-226. [PMCID: PMC3932534]

Kalinsky K, Crew KD, Maurer M, Refice S, Brafman L, Alvarez M, Sandoval R, Hershman DL (2014). Pre-surgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Investigations 32:150-157. [PMCID: PMC4435671]

Kalinsky K, Lim EA, Andreopoulou E, Desai AM, Jin Z, Tu Y, Hibshoosh H, Wang A, Greenlee H, Crew KD, Maurer M, Sparano JA, Hershman DL (2014). Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer. Cancer Investigations 32:439-444. [PMCID: PMC4428554]

Greenlee H, Crew KD, Mata J, McKinley PS, Rundle A, Zhang W, Yuyan L, Tsai WY, Hershman DL (2013). A pilot randomized controlled trial of a commercial diet and exercise weight loss intervention in minority breast cancer survivors. Obesity, 21:65-76. [PMCID: PMC4705911]

Greenlee H, Crew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai WY, Hershman DL (2013). Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Supportive Care in Cancer, 21:1077-1087. [PMCID: PMC3810608]

Hershman DL, Greenlee H, Awad D, Kalinsky K, Maurer M, Brafman L, Kranwinkel G, Tsai WY, Crew KD (2013). Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment, 138:795-806.

Hershman DL, Unger JM, Crew KD, Minasian LM, Moinpour CM, Hansen L, Lew DL, Fehrenbacher L, Wade JL, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013). Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. Journal of Clinical Oncology, 31:2627-2633. [PMCID: PMC3699727]

Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL (2012). Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer. Cancer Prevention Research, 5:1144-1154. [PMCID: PMC3816771]

Hillyer GC, Neugut AI, Crew KD, Kalinsky K, Maurer M, Rotsides DZ, Danaceau J, Hershman DL (2012). Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: A pilot study. Journal of Oncology Practice, 8:100-104. [PMCID: PMC3439234]

Hershman DL, Weimer LH, Wang A, Brafman L, Fuentes D, Awad D, Crew KD (2011). Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Research and Treatment, 125:767-774.

Kalinsky K, Sparano JA, Kim M, Crew KD, Maurer MA, Taback B, Feldman SM, Hibshoosh H, Wiechmann L, Adelson KB, Hershman DL (2011). Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. Journal of Clinical Oncology, 29(15 supplement):TPS147.

Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, Awad D, Shane E (2010). Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Endocrinology and Metabolism, 95:559-566. [PMCID: PMC2840866]

Crew KD, Capodice J, Greenlee H, Brafman L, Fuentes D, Awad D, Hershman DL (2010). Randomized, blinded, controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early stage breast cancer. Journal of Clinical Oncology, 28:1154-1160.

Yu B, Douglas N, Ferin MJ, Nakhuda GS, Crew KD, Lobo RA, Hershman DL (2010). Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer, 116:2099-2105. [PMCID: PMC3625425]

Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL (2009). High prevalence of vitamin D deficiency following supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. Journal of Clinical Oncology 27:2151-2156. [PMCID: PMC2674001]

Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL, Neugut AI, Santella RM (2009). Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prevention Research 2:598-604. [PMCID: PMC3077714]

Fu OS, Crew KD, Jacobson JS, Greenlee H, Yu G, Campbell J, Ortiz Y, Hershman DL (2009). Ethnicity and persistent symptom burden in breast cancer survivors. Journal of Cancer Survivorship 3:241-250.

Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E (2008). Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early stage breast cancer. Journal of Clinical Oncology 26:4739-4745. [PMCID: PMC2653138]

Crew KD, Neugut AI, Wang X, Jacobson JS, Grann VR, Raptis G, Hershman DL (2007). Racial disparities in treatment and survival of male breast cancer. Journal of Clinical Oncology 25:1089-1098.

Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007). Prevalence of joint symptoms in postmenopausal women on aromatase inhibitors for early stage breast cancer. Journal of Clinical Oncology 25:3877-3883.

Crew KD, Gammon MD, Terry MB, Zhang FF, Zablotska LB, Agrawal M, Shen J, Long CM, Eng SM, Sagiv SK, Tietelbaum SL, Neugut AI, Santella RM (2007). Polymorphisms in nucleotide excision repair genes, polycyclic aromatic hydrocarbon-DNA adducts, and breast cancer risk. Cancer Epidemiology, Biomarkers, and Prevention 16:2033-2041.

Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng, SM, Sagiv SK, Tietelbaum SL, Neugut AI, Santella RM (2007). Genetic polymorphisms in apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28:2548-2551.

Crew KD, Capodice J, Greenlee H, Apollo A, Sierra A, Brafman L, Fuentes D, Hershman DL (2007). Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy. Journal of Cancer Survivorship 1:283-291.

Nichols G, de Castro K, Wei L-X, Griffin M, Lin N, Oratzi A, Murty VVVS, Troxel A, Vahdat L, Hesdorffer C (2002). Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. Leukemia 16:1673-1679.

Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Bottinger EP, Danielpour D, Wakefield LM (1999). Loss of responsiveness to transforming growth factor b induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Research 59:4834-4842.

Wharton KA, Cook JM, Torres-Schumann S, de Castro K, Borod E, Phillips DA (1999). Genetic analysis of the bone morphogenetic protein-related gene, gbb, identifies multiple requirements during Drosophila development. Genetics 152:629-40.

Reviews and Editorials:

Lue JK, Crew KD (2015). Vitamin D and reduction of breast cancer risk. Current Breast Cancer Reports (in press).

Trivedi MS, Hershman DL, Crew KD (2015). Management of chemotherapy-induced peripheral neuropathy. American Journal of Hematology/Oncology (in press).

Trivedi MS, Crew KD (2015). Communication of multi-gene test results for hereditary breast cancer to patients and primary care providers. World Journal of Obstetrics and Gynecology (in press).

Coe AM, Crew KD (2015). Trends in the cost-effectiveness of chemoprevention for breast cancer: 2001-2015. Oncology & Hematology Review (in press).

Reimers LL, Crew KD, Terry MB (2015). Atypical hyperplasia of the breast. New England Journal of Medicine 372:1270-1271.

Crew KD (2015). Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. ASCO Educational Book e50-58.

Crew KD (2013). Vitamin D: Are we ready to supplement for breast cancer prevention and treatment? ISRN Oncology [Epub ahead of print]. [PMCID: PMC3600307]

Sivasubramanian P, Crew KD (2013). Biomarker endpoints for early-phase cancer-prevention studies. Current Breast Cancer Reports [Epub ahead of print]. [PMCID: PMC3600307]

Reimers L, Crew KD (2012). Tamoxifen vs. raloxifene vs. exemestane for chemoprevention. Current Breast Cancer Reports 4:207-215. [PMCID: PMC3744245]

Hershman DL, Cho C, Crew KD (2009). Management of complications from estrogen deprivation in breast cancer patients. Current Oncology Reports 11:29-36.

Crew KD, Neugut AI (2006). Aspirin and NSAIDs: Effects in breast and ovarian cancers. Current Opinion in Obstetrics and Gynecology 18:71-75.

Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World Journal of Gastroenterology 12:354-62. [PMCID: PMC4066052]

Crew KD, Neugut AI (2004). Epidemiology of upper gastrointestinal malignancies. Seminars in Oncology 31:450-64.

Books and Chapters:

Cardelli J, Coleman D, Crew KD (2013). "Flavonoids: Impact on Prostate Cancer and Breast Cancer." Inflammation and cancer: Mechanisms and dietary approaches for cancer prevention, ed. Kong T.

Kornreich D, Crew KD (2013). "Vitamin D receptor (VDR), as therapeutic cancer target." Encyclopedia of Cancer Therapeutic Targets, ed. Marshall JL.

Crew KD, Neugut AI, Antman KH (2005). "Malignant mesothelioma following radiation." Malignant Mesothelioma, eds. Pass HI, Vogelzang N, Carbone M. Springer, New York, NY.

Case Reports:

Crew KD, Cohen MH, Smith DH, Tiersten AD, Feirt NM, Hershman DL (2005). Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: A case report and review of the literature. Gynecologic Oncology 96:235-40.